• Thu, February 20, 2025
by: manilatimes
by: NextBigFuture
Microsoft Majorana 1 Chip Has 8 Qubits Right Now with a Roadmap to 1 Million Raw Qubits
• Fri, February 21, 2025
by: cnbctv18
India expands scope of key critical mineral classification to boost high-tech applications
by: kennesaw
by: MSN
Humanoid robot springs to life in 'dystopian' viral video: 'Straight out of science fiction'
by: MSN
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class novel PTH replacement therapy Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH since FDA approval SINGAPORE,

Read the Full manilatimes Article at:
https://www.manilatimes.net/2025/02/21/tmt-newswire/pr-newswire/first-and-only-treatment-for-chronic-hypoparathyroidism-approved-in-australia/2059832
Like: 👍